Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

• Status: Completed
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation phase (I) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001, and a dose expansion phase (II) which will characterize treatment of LAG525 as a single agent and in combination with PDR001 at the MTD or RP2D.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Spartalizumab

Criteria

Inclusion Criteria:

Phase I part:

• Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST version 1.1 (refer to Appendix 1), who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists

Phase II part:

• Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who have had disease progression following their last prior therapy and fit into one of the following groups:

• Group 1: NSCLC

• Group 2: Melanoma

• Group 3: Renal cancer

• Group 4: Mesothelioma

• Group 5: TNBC

• Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1

• Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy.

Exclusion Criteria:

• History of severe hypersensitivity reactions to study treatment ingredients or other mAbs

• Active, known or suspected autoimmune disease

• Active infection requiring systemic antibiotic therapy

• HIV infection. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

• Patients receiving chronic treatment with systemic steroid therapy, other than replacement-dose corticosteroids in the setting of adrenal insufficiency

• Patients receiving systemic treatment with any immunosuppressive medication

• Use of live vaccines against infectious disease within 4 weeks of initiation of study treatment

• Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment.

• Presence of symptomatic central nervous system (CNS) metastases or CNS metastases that require local CNS-directed therapy or increasing doses of corticosteroids within the prior 2 weeks

• History of drug-induced pneumonitis or current pneumonitis.